

The intestinal microbiota fuelling metabolic inflammation

Herbert Tilg¹*, Niv Zmora^{2,3,4}, Timon E. Adolph¹ and Eran Elinav^{1,2,5}*

Abstract | Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2 diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these disorders are characterized by alterations in the intestinal microbiota composition and its metabolites, which translocate from the gut across a disrupted intestinal barrier to affect various metabolic organs, such as the liver and adipose tissue, thereby contributing to metabolic inflammation. Here, we discuss some of the recently identified mechanisms that showcase the role of the intestinal microbiota and barrier dysfunction in metabolic inflammation. We propose a concept by which the gut microbiota fuels metabolic inflammation and dysregulation.

Chronic low-grade inflammation is a hallmark of many metabolic disorders, such as obesity and its related comorbidities, type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), which are rapidly increasing in prevalence worldwide^{1–7}. Atherosclerosis is exacerbated in these disorders and is a leading cause of cardiovascular morbidity and mortality. In comparison with acute inflammation, which is usually a physiological response to injury or infection, chronic inflammation in metabolic disorders, termed ‘metabolic inflammation’, is characterized by low-level local or systemic inflammatory responses. As such, several studies have associated these conditions with increased circulating levels of acute phase proteins (such as C-reactive protein (CRP), fibrinogen, haptoglobin, serum amyloid A, cytokines and chemokines)^{2,3,8–11}.

NAFLD has recently emerged as the most prevalent chronic liver disorder in developed countries and comprises a broad spectrum of manifestations, ranging from steatosis and its ensuing inflammatory condition termed nonalcoholic steatohepatitis (NASH), to liver cirrhosis and hepatocellular carcinoma. T2D and NAFLD often co-occur, as patients with T2D tend to develop NAFLD and patients with NAFLD are at risk for developing T2D¹². Similar to T2D, NAFLD is characterized by circulating proinflammatory mediators such as cytokines, acute phase proteins and adhesion molecules, which are present at high levels in patients with NASH^{13–18}.

Metabolic inflammation is considered sterile, as several non-infectious factors, such as nutrients and especially excess dietary lipid species (BOX 1), emerged as causative factors in experimental and clinical settings^{19–21}. This so-called lipotoxicity occurs in organs that are involved in lipid metabolism such as the liver, muscle or adipose tissue. As such, it may not be surprising that key regulators of lipid metabolism and

oxidative processes impact metabolic inflammation. For example, unresolved endoplasmic reticulum stress and oxidative stress are key drivers of an inflammatory response in metabolic dysregulation²². Similarly, hypoxia in expanding adipose tissue may trigger inflammatory responses^{23,24} and suppress the synthesis of anti-inflammatory adipokines (such as adiponectin)^{25,26}. It is well established that adipose tissue is an important cytokine sink in human obesity and related disorders^{27–30}. Estimates suggest that human visceral and subcutaneous adipose tissues contribute to 15–35% of the body’s total circulating IL-6 (REF.³¹). Notably, the degree of adipose tissue inflammation is correlated with the severity of liver inflammation in NAFLD³². These studies indicate that metabolic inflammation is a sterile process, fuelled by adipose and liver tissues^{4,5}.

In contrast to this notion, the gastrointestinal tract harbours a plethora of microorganisms, and specifically bacteria, that are a source of pathogen-associated molecular patterns (PAMPs) and metabolites. PAMPs communicate with the host by eliciting responses involving membrane-bound pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), or cytoplasmic PRRs such as NOD-like receptors or RIG-I-like receptors^{33–35}. Healthy subjects are characterized by a diverse composition of the intestinal microbiota and an intact intestinal barrier, which prevents penetration and systemic dissemination of bacteria and their mediators^{36–38}. By contrast, obesity and related metabolic disorders, such as T2D and NAFLD, exhibit profound functional and compositional alterations in the gut microbiota, collectively referred to as dysbiosis³⁹. Dysbiosis per se does not necessarily result in systemic inflammation; however, it is frequently associated with a bloom of commensals that may become detrimental (so-called pathobionts)⁴⁰. Additionally, obesity, T2D and NAFLD are characterized

¹Department of Internal Medicine, Gastroenterology, Hepatology, Metabolism & Endocrinology, Medical University Innsbruck, Innsbruck, Austria.

²Immunology Department, Weizmann Institute of Science, Rehovot, Israel.

³Digestive Centre, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel.

⁴Department of Internal Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel.

⁵Cancer-Microbiome Division, Deutsches Krebsforschungszentrum (DKFZ), Neuenheimer Feld 280, Heidelberg, Germany.

*e-mail: herbert.tilg@i-med.ac.at; eran.elinav@weizmann.ac.il

<https://doi.org/10.1038/s41577-019-0198-4>

Box 1 | Strategies to combat metabolic inflammation

Interventions designed to control metabolic inflammation pose a compelling means to reduce the risk for developing metabolic syndrome. Dietary habits (for instance, composition, quantity and timing) may impact metabolic inflammation. For instance, a high-fat diet promotes metabolic dysfunction in various organs, including the central nervous system, pancreas, liver, muscle, adipose tissue and vasculature²³³, and dietary lipids drive a low-grade inflammatory state through upregulation of Toll-like receptor 4-mediated inflammation in human peripheral blood monocytes⁴⁹. Studies in mice have shown that dietary lipids can also drive adipose tissue inflammation and insulin resistance in a microbiome-dependent manner²³⁴. In contrast, non-digestible carbohydrates (for example, dietary fibre) improve glucose homeostasis by enrichment of short-chain fatty acid-producing bacteria in the gut⁶³, although a study in humans found that weight reduction and anti-inflammatory effects mediated by dietary fibre was not associated with alterations in the gut microbiome²³⁵. Similarly, diets restricted in carbohydrates reduced circulating proinflammatory cytokines and improved fat metabolism in humans with obesity and nonalcoholic fatty liver disease²³⁶; omega-3 fatty acids and nicotinamide supplementation improved metabolic dysregulation in mice^{237,238}. Kynurenic acid reduced weight gain and promoted the expression of genes involved in lipid metabolism, thermogenesis and anti-inflammatory immune responses in adipose tissue²³⁹ and palmitic acid hydroxy stearic acids improved insulin sensitivity and reduced adipose tissue inflammation in mice²⁴⁰.

Experimental evidence also suggests that dietary timing impacts susceptibility to metabolic dysregulation. For example, time-restricted feeding ameliorated obesity and metabolic inflammation in mice²⁴¹. Additionally, exercise was associated with decreased levels of circulating proinflammatory cytokines and a greater gut microbiota diversity in humans²⁴² and ameliorated metabolic inflammation in mice²⁴³. Finally, not only lifestyle modification but also bariatric surgery is considered an effective intervention to trigger weight loss and treat metabolic disorders in severely obese patients. The effect achieved by surgery is partially mediated by reduction in calorie intake but may also be modulated by the intestinal microbiome²⁴⁴, bile acid metabolism²⁴⁵ and metabolic inflammation^{246,247}. A causal link between post-bariatric surgery microbiome alterations and attenuation of metabolic inflammation has been recently drawn in humans. Obese male human recipients with insulin resistance transplanted with faecal microbiota from human donors who underwent Roux-en-Y gastric bypass showed a decrease in insulin sensitivity and adipose inflammatory markers compared with recipients transplanted with microbiota from individuals with the metabolic syndrome²⁴⁸.

by an impaired and defective intestinal barrier^{41–43}. As a result of dysbiosis and intestinal barrier breach, it is perceived that the microbiota or its components (such as endotoxins) translocate into the circulation and instigate low-grade inflammation. In this Review, we examine the impact of the intestinal microbiota and its metabolites on intestinal permeability, metabolic inflammation and dysfunction and discuss how these insights can improve our understanding of human metabolic diseases.

The microbiota in metabolic disease

Dysbiosis in obesity. The advent of multi-omic sequencing in the past decade has allowed researchers to investigate the complexity of the intestinal microbiota in various human disorders^{44–46}. Evidence for a role of the intestinal microbiota on host metabolism came from studies in germ-free mice. Conventionally raised mice had significantly more total body fat than mice raised under germ-free conditions⁴⁷. Conventionalization of these germ-free mice with a caecum-derived microbial community resulted in a marked increase in total body fat content⁴⁷. Earlier observations had shown that colonization of germ-free mice profoundly affected the transcription of various factors in the intestinal tract regulating nutrient absorption, mucosal barrier function and metabolic functions⁴⁸. Pioneering studies in humans described a distinct gut microbiome signature

associated with obese states⁴⁹. Other studies found that obesity, the propensity to gain more weight, dyslipidaemia, insulin resistance and low-grade inflammation were more prevalent in subjects exhibiting low gut bacterial richness^{50,51}. Additionally, it was suggested that certain 'proinflammatory' bacterial strains, such as *Ruminococcus gnavus* or *Bacteroides* species, might dominate in obesity and 'anti-inflammatory' strains, such as *Faecalibacterium prausnitzii*, are less prevalent⁵². A certain intestinal microbiome signature may also contribute to weight regain in obese mice after successful dieting⁵³. Collectively, these studies suggest the existence of a gut microbial signature in obesity.

Dysbiosis in type 2 diabetes. Several landmark studies from the past several years have reported a microbiome signature in T2D and NAFLD^{54–56} (TABLE 1). Intestinal dysbiosis in T2D was characterized by a decrease in *Roseburia intestinalis* and *F. prausnitzii*⁵⁴. The altered microbiome was enriched in membrane transport of sugars, branched-chain amino acid transport and decreased butyrate biosynthesis. Enriched microbial genes mapped to oxidative stress signalling, suggesting a direct link between an altered microbiota composition and the inflammatory state in patients with T2D. European women with T2D demonstrated increased abundance of Lactobacillales (including *Lactobacillus gasseri* and *Streptococcus mutans*) and alterations in Clostridiales abundance (including *Clostridium clostridioforme* and other *Clostridium* species). Moreover, *R. intestinalis* and *F. prausnitzii*, both typical butyrate producers, were highly discriminant for T2D⁵⁵. Indeed, transfer of the intestinal microbiota (and its metabolites) from lean donors to patients with metabolic syndrome ameliorated insulin resistance⁵⁷. A recent report also showed that individuals with prediabetes exhibited an aberrant intestinal microbiota composition accompanied by decreased abundance of *Akkermansia muciniphila*⁵⁸. Several other studies have provided evidence for a gut microbiome signature in T2D or linked microbial functional alterations with features of T2D. For example, Pedersen et al. found increased levels of branched-chain amino acids in insulin resistance⁵⁹. Notably, *Prevotella copri* and *Bacteroides vulgatus*, two bacterial strains that are enriched in subjects with T2D, were able to promote insulin resistance and increased levels of branched-chain amino acids in rodents⁵⁹. Mice with diet-induced obesity and treated with *Ralstonia pickettii* exhibited increased insulin resistance compared with control animals, suggesting a role for *R. pickettii* in T2D⁶⁰. A potentially detrimental (proinflammatory) bacterial strain is *Bilophila wadsworthia*, which worsened high-fat diet (HFD)-induced metabolic dysfunction and hepatic steatosis in mice^{40,61}. Both pharmacological suppression of *B. wadsworthia* and treatment with *Lactobacillus rhamnosus* CNCM I-3690 improved metabolic inflammation, glycaemic control and intestinal barrier integrity. Similarly, certain bacterial strains, such as *Eubacterium hallii*, can ameliorate insulin resistance in rodents⁶². *E. hallii* treatment improved energy expenditure, increased faecal concentrations of butyrate and affected bile acid metabolism. Zhao et al. recently

Table 1 | Intestinal dysbiosis in type 2 diabetes and nonalcoholic fatty liver disease

Change	Type 2 diabetes ^a	Nonalcoholic fatty liver disease ^a	Refs
Dysbiosis			
Bacteroidales	↑ <i>Bacteroides</i> spp.	↑ <i>Bacteroides vulgatus</i> ^b	54,56
	↑ <i>Alistipes</i>	↓ <i>Alistipes putredinis</i> ^b	54,56
	↑ <i>Parabacteroides</i>	–	54
Firmicutes	↓↑ Clostridiales	–	54,55
	↑ <i>Clostridium</i> spp.	↓ <i>Ruminococcus obeum</i> ^b	54,56
	↓ <i>Eubacterium rectale</i>	↑↓ <i>Eubacterium rectale</i> ^b	54,56
	↓ <i>Faecalibacterium prausnitzii</i>	–	54
	↓ <i>Roseburia</i> spp.	–	54
	↑ <i>Lactobacillus gasseri</i>	–	55
	↑ <i>Streptococcus mutans</i>	–	55
Proteobacteria	↑ <i>Escherichia coli</i>	↑ <i>Escherichia coli</i> ^b	54,56
Verrucomicrobia	↓↑ <i>Akkermansia muciniphila</i>	–	54,264
Associated altered microbial functions			
	Sugar membrane transport, branched-chain amino acid transport, butyrate production	Amino acid metabolism, butyrate metabolism	54,56
Impact on experimental metabolic disease			
Detrimental	<i>Bacteroides vulgatus</i> , <i>Prevotella copri</i> , <i>Bilophila wadsworthia</i> , <i>Ralstonia pickettii</i>	–	59–61
Beneficial	<i>Lactobacillus rhamnosus</i> , <i>Lactobacillus gasseri</i> , <i>Eubacterium hallii</i> , <i>Akkermansia muciniphila</i>	VSL#3 (<i>Lactobacilli</i> , <i>Streptococcus thermophilus</i> , <i>Bifidobacterium</i>)	61,62,76,145,264

^aFor gut microbiome changes in obesity, we refer to recent reviews^{265,266}. ^bExamples of a consortium comprising 37 species.

ob/ob mice

A mouse model of metabolic dysregulation and obesity that arises from increased appetite due to a leptin mutation (that renders these mice functionally leptin deficient).

Metabolic endotoxaemia

A state that favours the translocation of microbial components (such as lipopolysaccharide) to the bloodstream, which promotes metabolic disease.

observed that certain dietary fibres promoted the synthesis of short-chain fatty acids (SCFAs) by manipulating the gut microbiota⁶³. Overgrowth of SCFA-producing bacteria directly correlated with improvements in glycaemic control (mirrored by decreased glycated haemoglobin levels), partly through upregulation of glucagon-like peptide 1 (GLP1). Interestingly, levels of potentially detrimental metabolites, such as indole or hydrogen sulfide, were reduced by dietary fibres. An analysis of eight studies supported the notion that dietary interventions in patients with T2D altered the gut microbiota and ameliorated metabolic dysfunction⁶⁴. Notably, dietary factors that drive metabolic dysregulation may also have a strong effect on the gut microbiota⁶⁵, a topic that is beyond the scope of this Review.

Dysbiosis in NAFLD. Increasing evidence indicates that the gut microbiota is involved in the pathogenesis of NAFLD^{56–69}. Recent human studies suggest an intestinal microbiome signature in NAFLD, with the dominance of certain phyla such as Proteobacteria⁷⁰. Furthermore, the faecal microbiome composition reflects the degree

of fibrosis in patients with NAFLD⁵⁶. Advanced fibrosis was associated with an increased abundance of Proteobacteria and *E. coli* and a decrease in Firmicutes, allowing microbiome profiling to accurately diagnose advanced fibrosis in NAFLD. Moreover, the faecal microbiome of 2-week-old infants born to obese mothers promoted the development of experimental NAFLD when transplanted in germ-free mice⁷¹. These data indicate that the intestinal microbiota impacts the susceptibility for NAFLD. Interestingly, in more advanced liver diseases, more than 50% of the species detected in gut microbiome samples were of buccal origin, suggesting that the oral microbiota could contribute to disease progression when present in the lower gastrointestinal tract⁷². Concordantly, ectopic colonization of oral bacteria in the gut has been shown to drive T helper 1 (T_H1) cell induction and inflammation in *Il10*^{−/−} mice⁷³.

Similar to these important observations in human NAFLD, microbial alterations have been linked to experimental NAFLD^{47,74}; more than 20 years ago, dietary prebiotics were shown to improve experimental hepatic steatosis⁷⁵. Furthermore, a 4-week therapy with VSL#3, a probiotic mixture comprising *Streptococcus thermophilus* and several strains within the *Lactobacillus* and *Bifidobacterium* genera, was as effective as therapy targeting tumour necrosis factor (TNF) in decreasing liver steatosis in *ob/ob* mice⁷⁶.

Collectively, these studies support the notion that obesity, T2D and NAFLD exhibit distinct gut microbiome signatures, characterized by a bloom of potentially harmful taxa and suppression of beneficial taxa. However, it must be acknowledged that the behaviour of certain bacteria may be context specific and determined by the integrated signature of host-related and microbiome-related factors that define their composite role as pathobionts or commensals⁷⁷.

Barrier dysfunction in metabolic disease

The interface partitioning the gastrointestinal microbiome from the underlying host tissue is a pivotal signalling hub between these two compartments, and breach of this interface has been linked to detrimental metabolic consequences. Pioneering work demonstrated that feeding mice a HFD modified the gut microbiome and triggered an influx of bacteria-derived lipopolysaccharides (LPS) into the systemic circulation (a state termed ‘metabolic endotoxaemia’), which may contribute to an increased inflammatory tone, obesity and diabetes⁷⁸. This observation has been replicated in work by others showing increased permeability across the gut barrier in the jejunum and colon of a mouse model for obesity⁷⁹ and in the small intestine of a rat model for NASH^{79,80}. In humans with T2D, increased intestinal permeability was suggested more than three decades ago⁴³ and ever since has been described along with leakage of bacteria or bacterial products across the intestinal barrier during consumption of a HFD⁸¹. However, gut barrier dysfunction has been inconsistently described in other manifestations of the metabolic syndrome such as obesity^{82–85} and NASH^{86–91}. These discrepancies may derive from methodological issues, such as the diversity of means to assess gut permeability in humans, ranging from morphological

analyses using histology and electron microscopy, to functional analyses such as enteral administration of non-digestible markers or measurement of translocated microbial PAMPs. Results may be altered based on the part of the gastrointestinal tract investigated and the molecular size of the administered marker. Unlike animal models, human studies are particularly prone to environmental and host bias; individuals may differ in the capacity of endotoxin production by their gut microbiome consortia, or in factors affecting absorption (such as dietary intake, gut motility, distribution of the markers in the body, use of interacting drugs and kidney function), which may reduce or confound statistical trends and complicate their interpretation (see below).

Over the years, research has elucidated the role of the host–microbiome interface and identified that intestinal epithelial cells constitute not only a physical barrier but also harbour immunological properties⁹². In this section, we describe mucosal mechanisms that orchestrate the host–microorganism crosstalk, disruption of which can instigate metabolic derangements. We discuss interventions that restore intestinal barrier integrity as novel therapeutic approaches against metabolic syndrome.

Molecular immune mechanisms of intestinal barrier disruption. Segregation between the host gut epithelium and the microbiome at homeostasis is maintained by various mechanisms that favour a tolerogenic immune response. In the small intestine, this is achieved primarily by PRRs, antimicrobial peptides and secreted IgA, and an immune milieu consisting of a cytokine environment that includes IL-33, IL-10 and transforming growth factor- β (TGF β) as well as cells such as CD103⁺ dendritic cells and regulatory T cells. In the large intestine, compartmentalization also relies on a thick continuous mucus layer^{93,94}. HFD feeding and obesity bring about anatomical and functional alterations to the intestinal barrier. Anatomically, humans with obesity exhibit jejunal villus hyperplasia and an increased surface area of exchange with the luminal content, which might be a trigger for changes in the immune compartment. In mice, proinflammatory changes have been observed during HFD feeding, starting in the colon with an increase in IL-17-producing $\gamma\delta$ T cells and a concomitant reduction in regulatory T cells⁹⁵, and continuing with an increase in interferon- γ (IFN γ)-producing T_H1 cells and CD8⁺ T cells along with a concomitant reduction in regulatory T cells in both the colon and the small intestine. Another study suggested a microbiome-mediated decrease in T_H17 cells in the ileal lamina propria of mice consuming a HFD at the onset of metabolic disease⁹⁶. Additionally, HFD exposure resulted in a depletion of eosinophils in the small intestine, which may drive increased paracellular permeability⁹⁷. Likewise, in humans with obesity, CD8⁺ T cells shifted from the lamina propria to the epithelium in the jejunum⁹⁸. These immune alterations coincided with a proinflammatory intestinal cytokine environment in both mice^{95,96} and humans⁹⁸, which was suggested to reduce intestinal insulin signalling in enterocytes *in vitro*⁹⁸. Attenuation of this proinflammatory state, either by genetic manipulation or by exogenous administration of an anti-inflammatory agent, led

to enhanced intestinal barrier function in mouse models for HFD-induced obesity^{95,99}. The cytokine landscape in mice in obesity and insulin resistance is summarized by biogeographical location in a recent review¹⁰⁰.

Containment of the commensal microbiome by the intestinal immune system is crucial to preventing chronic systemic inflammation. Research in mice showed that, in homeostasis, mucosa-associated gut commensals sensed by the Mincle–SYK signalling pathway in small intestinal dendritic cells in Peyer's patches induce IL-6 and IL-23p19 production, which in turn stimulate intestinal T cells and innate lymphoid cells (ILCs) to secrete IL-17 and IL-22 (REF.¹⁰¹). Small-intestinal mucosal immune cells (such as ROR γ t-dependent T_H17 cells and ILC3s) contribute to the induction of antimicrobial peptides (such as REG3 γ) and IgA to prevent the translocation of commensal bacteria and systemic inflammation associated with chronic diseases^{102–104}. Specifically, ROR γ t⁺ ILCs express membrane-bound lymphotoxin to regulate IgA production by dendritic cell-derived inducible nitric oxide synthase (iNOS; also known as NOS2) induction, and soluble lymphotoxin to regulate IgA production by controlling T cell homing to the small intestinal lamina propria¹⁰³. Interestingly, mice deficient in lymphotoxin genes and fed a HFD were protected from diet-induced obesity due to an altered microbiome composition, which possibly involved segmented filamentous bacteria^{105,106}. The contribution of antimicrobial peptides to large intestinal barrier integrity has been recently illuminated in transgenic mice overexpressing the human antimicrobial peptide REG3A in hepatocytes¹⁰⁷. These mice showed a distinct microbiome composition, which protected them against chemically induced colitis, a trait that was transmissible to wild-type mice by co-housing or by faecal microbiota transplantation. Whether antimicrobial peptide-mediated barrier augmentation may also ameliorate metabolic inflammation merits further studies.

Mice harbouring a genetic aberration in the Mincle–SYK pathway exhibited liver inflammation and impaired lipid metabolism — that is, increased expression of lipogenic genes and accumulation of diacylglycerides and fatty acids¹⁰¹. Furthermore, IL-22 and its upstream inducer IL-23 regulate the production of antimicrobial peptides and thereby repress semi-invasive proatherogenic microbiome members, which produce LPS and components of the trimethylamine *N*-oxide (TMAO) biosynthesis pathway in atherosclerosis-prone mice¹⁰⁸. Interestingly, a similar mechanism was described to protect against intestinal damage and inflammation^{109–111}. Of note, a breach in the intestinal barrier by the microbiome has been previously associated with the induction of commensal-specific IgG antibodies, which implies a systemic immune response in metabolic dysbiosis, and indeed circulating IgG against commensals has been reported in humans with obesity and diabetes and in HFD-fed mice¹¹². Collectively, this host–microbiome reciprocal signalling circuit serves as a rheostat for immune tuning and microbiome containment, which is pivotal in damping metabolic endotoxaemia.

Host–microbiome interactions are perturbed upon HFD feeding and obesity, and their metabolic aftermath can be recapitulated or corrected in genetically

manipulated mice. For example, mice fed a HFD showed a microbiome-mediated decrease in T_H17 cells in the ileal lamina propria⁹⁶ and obese mice showed reduced IL-22 production from colonic ILCs upon immune stimulation¹¹³. IL-22R1-deficient mice showed increased weight gain and developed glucose intolerance and insulin resistance, which was remediable by IL-22 supplementation. This beneficial effect was mediated, in part, by the reduction of endotoxaemia, and not by microbiome alterations¹¹³. Additionally, obese mice exhibited increased activity of intestinal and colonic indoleamine 2,3-dioxygenase, which shifted tryptophan metabolism from indole derivative and IL-22 production to kynurenine production, a finding that was also suggested in humans⁸⁵. Mice with genetic deletion of this enzyme maintained gut mucosal barrier integrity, exhibited decreased endotoxaemia, increased insulin sensitivity and regulated hepatic lipid metabolism. This beneficial metabolic phenotype could be transferred between mice by co-housing or by faecal microbiota transplantation⁸⁵. Of note, caution should be practised when attempting to translate these findings from the intestinal niche to other metabolic organs, and from mice to humans.

As opposed to the favourable metabolic effects observed in the mouse gut, T_H17 and T_H22 cells were elevated in adipose tissue of humans with obesity or diabetes^{114,115}, and IL-17 plasma levels were elevated in women with obesity¹¹⁶. IL-17 has been associated with NAFLD progression¹¹⁷ but also with protection against diet-induced obesity in mice¹¹⁸. Additionally, IL-22 was shown to participate in obesity-induced adipose tissue inflammation through IL-1 β induction¹¹⁴ and to instigate insulin resistance in the liver and muscle *in vitro*¹¹⁵. Further studies are warranted to elucidate the role of IL-22 in metabolism and immunity in humans.

Other causative links between the intestinal immune system, the gut microbiome and host metabolism were elucidated by genetic deletion of PRRs in mouse models of the metabolic syndrome. MyD88, an adaptor molecule involved in the activation of most TLRs, has been suggested to have a role in metabolic disturbances, although its effect is ambivalent. Conventional *Myd88*-knockout mice showed increased fat mass and body weight, and exacerbated glucose intolerance and insulin resistance, concurrent with bacterial translocation to mesenteric adipose tissue¹¹⁹. However, mice harbouring an inducible deletion of *Myd88* in epithelial cells exhibited enhanced gut barrier integrity, augmented antimicrobial peptide expression and increased abundance of intestinal regulatory T cells, and they were protected against dietary-induced obesity, diabetes and hepatic steatosis¹²⁰. Conversely, mice deficient in TLR5 developed dysbiosis, which prompted low-grade inflammation, impaired insulin signalling and hyperphagia (excessive eating), and other aspects of the metabolic syndrome¹²¹. Mice deficient in components of the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome exhibited severe NASH following a methionine-choline-deficient diet, which was mediated by dysbiosis⁷⁴; however, other studies showed that NLRP3 inflammasome activation impaired insulin signalling¹²², and its inhibition resulted in protection against obesity-induced insulin resistance¹²³.

The NLRP6 inflammasome was shown to interact with microbiome-associated metabolites to govern the intestinal antimicrobial peptide landscape and prevent dysbiosis and ensuing features of the metabolic syndrome^{124,125}. Mice deficient in the PRR nucleotide oligomerization domain-containing protein 1 (NOD1) or CD14 (a co-receptor for the TLR that senses LPS) and fed a HFD were protected from systemic bacterial translocation and the development of glucose intolerance and fat mass gain¹¹⁹. However, HFD-consuming NOD2-deficient mice failed to demonstrate the same protective effect¹¹⁹ and even showed increased obesity, liver inflammation and exacerbated insulin resistance¹²⁶. Metabolic dysregulation was transferrable to germ-free mice through faecal microbiota transplantation, demonstrating a mechanistic role for PRRs that sense the intestinal microbiota and dictate metabolic phenotypes. Similarly, mice deficient in the channel protein ORAI1, which exhibit impaired pancreatic antimicrobial peptide secretion, showed bacterial overgrowth, dysbiosis and increased intestinal permeability, leading to bacterial translocation and mortality¹²⁷.

In light of the mucosal proinflammatory milieu in metabolic disorders, a compelling therapeutic approach would be to target and suppress immune pathways. For example, treatment with the anti-inflammatory drug 5-aminosalicylic acid in mice reversed bowel inflammation, reduced gut permeability and endotoxaemia, and ameliorated fasting glucose, fasting insulin and insulin resistance⁹⁵.

Factors regulating intestinal barrier integrity and potential therapeutic targets. Dietary composition, and specifically nutrition rich in fat, can impact intestinal permeability, as a HFD promoted intestinal inflammation, which preceded the onset of weight gain in mice^{96,128}. It has been shown, *in vitro* and in mouse models, that in the presence of dietary lipids LPS can be transported through the epithelial barrier via the transcellular route by chylomicrons (rather than the conventional paracellular route)^{129,130}. Correspondingly, a study in patients with severe obesity showed that jejunal permeability increased compared with healthy controls upon a lipid challenge⁸⁴, and another study found a correlation between jejunal epithelial T cell densities and an unbalanced diet (reduced carbohydrate in lipid-rich diet) in humans with obesity⁹⁸, providing a potential explanation to the discrepancies in results observed in human trials and suggesting that factors other than obesity per se mediate intestinal barrier breach in humans. Similarly, mice with hyperglycaemia exhibited increased colonic (and possibly also small intestinal) permeability¹³¹, and mice fed diets rich in fructose, fat or both exhibited impaired duodenal barrier integrity, endotoxaemia and NAFLD¹³². Dietary supplements, such as emulsifiers, may also disrupt the gut barrier integrity by promoting gut microbial dysbiosis and allowing for bacterial encroachment, thereby inducing low-grade inflammation and resulting in features of the metabolic syndrome in mice¹³³. The timing and quantity of food also dictate plasma LPS levels, as HFD-fed mice showed diurnal variations in endotoxaemia, which peaked towards the end of the dark phase⁷⁸, and short-term starvation attenuated intestinal barrier leakage in

Chylomicrons

Transport vesicles (so-called lipoprotein particles) for absorbed dietary lipids.

humans¹³⁴. Other intraluminal mechanisms accounting for intestinal barrier breach include increased bile acid concentrations (demonstrated in vitro)¹³⁵ and the presence of osmotic diarrhoea (demonstrated in mice), which decreases mucus thickness and thus exposes the epithelium to direct contact with bacteria¹³⁶.

The gut microbiome is a key player in intestinal barrier disruption, as its absence in antibiotic-treated mice protects against HFD-induced intestinal permeability and its metabolic consequences^{131,137}. Some dietary regimens drive microbiome shifts, which in turn contribute to barrier breach in various ways. Mice fed a HFD show an increased proportion of LPS-containing caecal microbiome⁷⁸, and mice chronically or intermittently fed a fibre-deprived diet exhibit dysbiosis that favours the use of the colonic mucus as a nutrient source, thus exacerbating pathogen infection¹³⁸ and increasing mucus layer permeability, remediable with microbiome transplantation from chow-fed mice¹³⁹.

Microbiome-related strategies to ameliorate intestinal barrier permeability involve the administration of microbiome-altering compounds (prebiotics), supplementation of bacteria known to confer beneficial roles on the gut barrier (probiotics) or treatment with bacteria-derived by-products (postbiotics). A plausible prebiotic therapy is the administration of the alkaloid berberine, which ameliorated intestinal barrier function, either directly or by modification of the gut microbiome, attenuating endotoxaemia and improving weight gain, dyslipidaemia and NASH in HFD-fed rats¹⁴⁰. Oligofructose supplementation to obese mice ameliorated gut barrier integrity and improved systemic and hepatic inflammation, possibly through a GLP2-dependent mechanism¹⁴¹. Likewise, curcumin (a substance in turmeric) or non-absorbable antibiotics improved intestinal barrier function and attenuated endotoxaemia, and thereby reduced atherosclerosis and glucose intolerance in HFD-consuming low-density lipoprotein receptor-deficient mice¹⁴².

Several probiotic therapies have been proved effective in reducing intestinal permeability in animal models. *A. muciniphila* supplementation was suggested to augment mucus thickness and tight junction expression and protect against gut leakiness in a mouse model for alcoholic liver disease¹⁴³. Concordantly, the same bacterium, or a specific protein isolated from its outer membrane, enhanced gut barrier integrity, decreased body weight and fat-mass gain, attenuated dyslipidaemia and improved glucose tolerance in HFD-consuming mice¹⁴⁴. *Lactobacillus rhamnosus* GG supernatant prevented alcohol-induced intestinal leakage, endotoxaemia and liver injury in mice¹⁴⁵. *Lactobacillus reuteri* improved the features of metabolic syndrome by production of aryl hydrocarbon receptor ligands in mice¹⁴⁶. *Bifidobacterium longum* NCC 2705 and inulin supplementation to mice consuming a fibre-depleted diet ameliorated mucus growth and reduced mucus permeability, respectively, although there was no improvement in metabolic parameters¹³⁹. *Parabacteroides distasonis* elevated lithocholic acid and ursodeoxycholic acid (UDCA) in the bile of HFD-fed mice and *ob/ob* mice and thereby upregulated ileal tight junction protein expression and reduced

endotoxaemia, which in turn decreased weight gain, hyperglycaemia and hepatic steatosis compared with untreated mice¹⁴⁷. Finally, in humans, treatment of obesity with *Bifidobacterium adolescentis* IVS-1, *Bifidobacterium lactis* BB-12 or the prebiotic galacto-oligosaccharides resulted in improved colonic permeability, although no changes in markers of endotoxaemia ensued¹⁴⁸.

An alternative postbiotic approach is the direct administration of bile acids shown to have a beneficial metabolic effect on the host. Cholic acid ameliorates insulin sensitivity and reduces obesity in mice through the activation of G protein-coupled bile acid receptor TGR5 and downstream NLRP3 inhibition¹⁴⁹. Similarly, UDCA administration to mice stimulated epithelial cell migration and was protective against intestinal injury¹⁵⁰, and a mixture of UDCA and lithocholic acid increased gut barrier integrity and subsequently improved hyperlipidaemia and hepatic steatosis¹⁴⁷. Semisynthetic farnesoid X receptor agonists proved to be effective in attenuating epithelial permeability in chemically induced colitis in mice; however, whether such effects contribute to metabolic syndrome mitigation merits further studies¹⁵¹. Of note, bile salt-based therapies should be adjusted from mice to humans, as the composition of bile and the metabolism of bile salts differ between organisms¹⁵². Other postbiotic therapies include aryl hydrocarbon receptor ligands, which alleviated intestinal barrier dysfunction in HFD-fed mice and in vitro¹⁴⁶.

Together, animal research on prebiotic, probiotic and postbiotic therapies holds promise in enhancing gut barrier integrity to combat metabolic inflammation; however, evidence in humans is still sparse and insufficient. Future studies should focus on devising therapeutic strategies that overcome the current shortcomings in this field (see, for instance, REF.¹⁵³).

Gut permeability is enhanced in T2D by other mechanisms that do not necessarily involve the microbiome. For example, hyperglycaemia, either genetically, chemically or diet induced, was shown to compromise intestinal barrier integrity in mice through GLUT2-dependent reprogramming of the intestinal epithelial cell transcriptome and disruption of tight and adherence junctions¹³¹. Additionally, fatty acid synthase, an enzyme responsible for mucus secretion, was reduced in the colonic epithelium of diabetic mice manifesting as a diminished inner mucus layer, the presence of bacteria in the epithelium and systemic endotoxaemia, which was corrected with insulin¹⁵⁴.

Another pathway modulating gut permeability pertains to the endocannabinoid system, as blockade of cannabinoid receptor 1 modulated tight junction protein localization, reduced endotoxaemia and consequently decreased obesity and glycaemia in mice. Concordantly, administration of a cannabinoid receptor agonist worsened endotoxaemia¹⁵⁵.

In summary, the host–microbiome interface transduces aberrant gut signals derived from the diet or dysbiotic bacterial consortia to local immune responses, resulting in barrier breach, and as such it may be regarded as another hit of metabolic inflammation (FIG. 1). This barrier disruption may contribute, in turn, to systemic chronic inflammation and end-organ dysfunction, leading to metabolic disease.

Berberine

A plant-derived alkaloid of an ancient Chinese herb, *Coptis chinensis*.

Low-density lipoprotein receptor-deficient mice

A mouse model of atherosclerosis caused by a targeted deletion of the gene encoding the low-density lipoprotein receptor (LDLR). In humans, homozygous mutations in *LDLR* cause familial hypercholesterolaemia, a disease characterized by pronounced hyperlipidaemia and accelerated atherosclerotic cardiovascular disease.




Fig. 1 | Gut barrier breach in metabolic diseases in mouse models. a | The integrity of the small intestinal epithelium is maintained by a variety of host exogenous and endogenous factors. Exogenous factors include the gut microbiome and compounds such as intraluminal dietary constituents and microbiome-derived metabolites. In a metabolically healthy state (achieved by a high-fibre diet), the gut microbiome mediates intestinal integrity through direct mechanisms, such as sampling of microbial antigens from the intestinal lumen by dendritic cells (DCs) and triggering ROR γ t-dependent cell activation and differentiation, leading to secretion of mucus, antimicrobial peptides (AMPs) and IgA. Alternatively, sensing of microbial metabolites by inflammasomes also leads to AMP secretion. These events, and a tolerogenic immune milieu, promote homeostasis with the microbiota. In addition, the microbiome maintains intestinal barrier function through indirect cues such as signalling via secondary bile acids or aryl hydrocarbon receptor (AHR) agonists. Host endogenous factors also determine gut barrier integrity, including blood insulinaemia, which regulates mucus secretion via fatty acid synthase (FAS). **b** | Dysbiosis induced by dietary, mechanical or genetic factors may result in metabolic derangements through increased lipopolysaccharide (LPS) expression, driving Toll-like receptor (TLR) signalling and endotoxaemia by mucus layer degradation or by production of proatherogenic compounds. These events are accompanied by alterations in intestinal lamina propria cell populations and the cytokine landscape. These proinflammatory changes associated with intestinal barrier disruption contribute to metabolic inflammation. Finally, host blood glycaemia induces barrier dysfunction through glucose transporter 2 (GLUT2). FXR, farnesoid X receptor; GLP, glucagon-like peptide; IFN γ , interferon- γ ; ILC3, type 3 innate lymphoid cell; iNOS, inducible nitric oxide synthase; LT, lymphotoxin; NF- κ B, nuclear factor- κ B; NLRP3, NOD-, LRR- and pyrin domain-containing protein 3; SAA, serum amyloid A; SFB, segmented filamentous bacteria; T_H cell, T follicular helper cell; T_H cell, T helper cell; TMA, trimethylamine; T_{reg} cell, regulatory T cell.

Systemic microbiota and its metabolites

The liver is a critical gatekeeper of blood flow from the portal vein draining the intestine. Even in health, the liver is constantly challenged by metabolic stress deriving from intestinal bacteria and their metabolites. An intact intestinal epithelial barrier might protect the liver from overwhelming bacterial exposure. Whether hepatic

diseases such as steatosis in NAFLD and T2D affect the liver's capacity to detect and respond to bacteria and their derived compounds is currently unknown¹⁵⁶. However, increased circulating levels of endotoxins in obesity, T2D and NAFLD, as described in this section, support the notion that the steatotic liver might have an impaired capacity to clear bacterial components.

Box 2 | **Concept of microbiota-controlled metabolic inflammation**

An array of bacterial components or pathogen-associated molecular patterns, such as lipopolysaccharides²⁴⁹, flagellin²⁵⁰, peptidoglycan²⁵¹, ADP-heptose and lipoteichoic acid²⁵², elicit proinflammatory responses by innate and adaptive immune cells. Pathogen-associated molecular patterns are detected by specialized immune cells, such as tissue-resident dendritic cells and macrophages, which are equipped with a large repertoire of pathogen-recognition receptors such as Toll-like receptors and NOD-like receptors^{253,254}. Receptor activation potentially triggers the production of proinflammatory mediators (such as cytokines, chemokines and oxidative perturbations²⁰⁴) that fuel metabolic inflammation. Other immune cells, such as mucosa-associated invariant T cells, natural killer T cells and regulatory T cells, can modulate metabolic inflammation^{255–258}. Immune cells may be primed in the intestine and migrate to distant organs (such as the liver and adipose tissue) or are directly recruited to metabolically active tissues to modulate metabolic inflammation²⁵⁹.

Besides microbial signals, the immune system may also respond to cellular stress and tissue injury with an inflammatory response in metabolic diseases. For example, DNA damage²⁶⁰, endoplasmic reticulum stress²⁶¹ or damage-associated molecular patterns (such as double-stranded DNA, mitochondrial DNA and ATP) released during tissue injury²⁶² can perturb immune functions and potentially lead to a chronic inflammatory condition in metabolic disorders.

Bacterial signals may not only modulate the immune system, but also the function of the central nervous system¹⁸⁷. The study of the gut–brain axis has gained momentum in neurological diseases^{231,232}, which may also become relevant in behavioural sciences. For example, *Escherichia coli* proteins regulate host satiety in rats²⁶³.

Endotoxin promotes metabolic inflammation. A plethora of PAMPs and bacterial metabolites may contribute to metabolic inflammation and disease in mammals (BOX 2). Several landmark studies have established a major role for endotoxaemia as a driver of metabolic diseases^{78–81}. Endotoxaemia and its markers (elevated serum LPS and LPS-binding protein) were associated with increased risk of obesity and T2D in humans^{157,158}, and postprandial endotoxaemia was suggested to promote the development of T2D¹⁵⁹. In patients with T2D, endotoxaemia correlated with disease exacerbation. Furthermore, endotoxin administration to mice and healthy humans resulted in systemic and adipose tissue inflammation paralleled by insulin resistance, verifying that endotoxin affects insulin sensitivity¹⁶⁰. This metabolic dysregulation could be abolished by antibiotic treatment in diet-induced and genetically induced obese mice^{137,161}. Likewise, in patients with NAFLD, endotoxaemia was directly correlated with the degree of liver inflammation and fibrosis¹⁶².

One mechanism by which endotoxin modulates metabolic dysregulation could involve adipose tissue homeostasis as metabolic endotoxaemia increased the proliferation of preadipocytes and induced adipose tissue inflammation, which was dependent on CD14 (REF. ¹⁶³). The absence of CD14 in *ob/ob* mice mimicked the metabolically beneficial and anti-inflammatory effects of antibiotics¹³⁷. Notably, MyD88-dependent TLR signalling in intestinal epithelial cells promotes diet-induced obesity, diabetes and inflammation¹²⁰, and the progression of NAFLD is controlled by TLR4 (REF. ¹⁶⁴).

Several environmental factors, predominantly diet, impact endotoxaemia. A HFD led to the expansion of LPS-containing bacteria and increased plasma LPS concentrations⁷⁸. In humans, high-energy intake was correlated with serum LPS levels in a large French male cohort¹⁶⁵. Similarly, administration of a 4-week-long HFD (Western style diet) to healthy subjects resulted in

a 71% increase in endotoxin plasma levels, which was not observed after a prudent-style diet, suggesting that a HFD-induced barrier dysfunction and/or alteration of gut microbiota might be involved⁸¹. In contrast, the use of prebiotic oligofructose not only reduced endotoxaemia but also restored intestinal concentrations of *Bifidobacteria* and glucose tolerance¹⁶⁶. Similarly, functional changes of the gut microbiota by calorie restriction have been shown to lower the expression of key bacterial enzymes required for lipid A biosynthesis, a key component of LPS, and calorie restriction resulted in lower LPS concentrations and metabolic improvements in mice¹⁶⁷.

In summary, these studies support a critical role for endotoxin in metabolic inflammation. Which bacterial strains contribute to metabolic phenotypes remains largely elusive; however, it seems that some bacteria express LPS subtypes that have higher immunogenicity than others¹⁶⁸. In this respect, Fei et al. isolated *Enterobacter cloacae* B29 from a morbidly obese subject and colonization of this strain in germ-free mice recapitulated metabolic disease¹⁶⁹.

Bacterial components and metabolites control metabolic dysfunction. Studies in the past few years have highlighted a role for various bacterial metabolites in the exacerbation or modulation of metabolic dysfunction^{37,170}. Peptidoglycan-based bacterial cell wall components modulate inflammatory responses by stimulating the intracellular sensors NOD1 and NOD2. Signalling through NOD1 primes the innate immune system¹⁷¹ and expands the number of ileal $\gamma\delta$ T cells and promotes the release of the proinflammatory cytokine IL-17A from the mouse intestine, which in turn enhances the lifespan of circulating phagocytes in steady state¹⁷². These sensors may also contribute to metabolic inflammation and regulate insulin resistance, as HFD feeding of mice increased the levels of circulating NOD1 activators¹⁷³. Injections of a NOD1 ligand to mice induced adipose tissue and hepatic inflammation and systemic insulin resistance, whereas NOD1-deficient mice were protected from obesity-induced inflammation¹⁷⁴, and mice with a specific deletion of NOD1 in haematopoietic cells showed reduced adipose tissue-infiltrating proinflammatory macrophages¹⁷³. Conversely, NOD2-activating muramyl dipeptide triggered anti-inflammatory and insulin-sensitizing effects in HFD-fed or LPS-treated mice, mediated by interferon regulatory factor 4 (REF. ¹⁷⁵).

Dietary nutrients, especially phosphatidylcholine, choline and carnitine, are processed by the intestinal microbiota to produce trimethylamine, which is converted in the liver into TMAO by flavin-containing monooxygenases. TMAO levels correlate with atherosclerosis, cardiovascular complications and clinical outcomes, as this metabolite drives inflammation and platelet activation^{176–178}. Increased TMAO levels are indicative of T2D and correlate with glycaemic control, cardiovascular complications and NAFLD^{179–183}, although the mechanisms of TMAO action may be diverse¹⁸⁴.

Other bacterial products, such as SCFAs, may be metabolically protective¹⁸⁵. SCFAs are mainly derived from the fermentation of complex carbohydrates (for instance, fibre)

and have emerged as key factors orchestrating host physiology and disease, as recently reviewed elsewhere¹⁸⁶. SCFAs can directly activate G protein-coupled receptors, inhibit histone deacetylases and serve as a major energy source for intestinal epithelial cells. Their specific binding to G protein-coupled receptors allows them to exert protective immune and metabolic functions¹⁸⁶. Furthermore, production of the SCFA acetate by the microbiota was shown to activate the parasympathetic nervous system and promote insulin secretion and weight gain¹⁸⁷.

Similarly, flavonoids are diet-derived compounds metabolized by the microbiome and shown to contribute to enhanced energy expenditure in mice by inducing thermogenesis in brown adipose tissue. Consequently, exogenous administration of flavonoids as a postbiotic intervention ameliorated excessive secondary weight gain in mice⁵³. Additionally, the gut microbiome can modulate metabolic inflammation by affecting host-derived molecules. For instance, the microbiome has a regulatory role in bile acid synthesis and biotransformation, which in turn affect metabolic processes, such as liver steatosis, adipose tissue browning and insulin signalling, by acting on farnesoid X receptor and TGR5 (REF.¹⁵²).

A recent study investigated the relationship between the plasma and urine metabolomes, faecal metagenomics and the hepatic transcriptome¹⁸⁸. The degree of hepatic steatosis correlated with a gut microbial signature, characterized by reduced microbial gene richness, and increased relative abundances of Proteobacteria, Actinobacteria and Verrucomicrobia. Reduced microbial gene richness was associated with steatosis and an increase in the amount of branched-chain amino acids. Moreover, phenylacetate, a faecal (mainly bacteria derived) degradation product of essential amino acids was associated with steatosis. Phenylacetate enhanced hepatic lipid accumulation by increasing branched-chain amino acid use. Faecal transfer from obese women with high-grade steatosis into mice promoted hepatic steatosis, similar to feeding with phenylacetate¹⁸⁸.

Koh et al. recently identified the bacterial metabolite imidazole propionate as a factor affecting insulin signalling¹⁸⁹. In their study, the authors assessed portal vein blood from subjects with and without T2D for metabolically active compounds. They identified imidazole propionate as a histidine-derived microbial metabolite commonly found in patients with T2D. Notably, imidazole propionate impaired insulin signalling in mice in a mechanistic target of rapamycin complex 1 (mTORC1)-mediated pathway, a pathway that was found overexpressed also in livers of patients with T2D¹⁸⁹.

Together, bacterial structural components and metabolites secreted from bacterial processing of diet-derived and host-derived molecules modulate metabolic inflammation through various mechanisms. Of note, metabolic inflammation and the gut microbiome assembly are governed by additional factors, namely dietary habits, exercise and others (BOX 1).

Circulating or tissue microbiome: fact or fiction? Impaired intestinal barrier function and the influx of bacteria-derived metabolites into the portal system in metabolic disorders have raised the question of whether

bacteria or their antigens can reach the circulation or even distant organs. Amar et al. showed that commensal DNA could be detected in the blood and adipose tissue of HFD-fed mice¹¹⁹. The same group detected distinct blood bacterial dysbiosis involving a bloom of Proteobacteria in patients with metabolic syndrome and cardiovascular events¹⁹⁰. The blood fraction and state in which the bacteria can be found (whether intracellularly in dormancy, as previously described¹⁹¹) remains to be determined. It has been proposed that bacteria reside in the leukocyte and platelet fractions of whole blood, but not in the plasma, of healthy humans¹⁹². Likewise, Schierwagen et al. found evidence for a circulating microbiome in the buffy coat fraction of central, hepatic/portal venous and peripheral blood from seven patients with liver cirrhosis undergoing transjugular portosystemic shunting¹⁹³. Particularly, Proteobacteria sequences could be detected in the blood, which was somewhat fraction specific. Importantly, in some patients the authors were able to cultivate bacteria, suggesting that circulating sequences were derived from living bacteria.

A blood microbiome signature for NAFLD-associated liver fibrosis has also been described in a small cohort of patients with severe obesity¹⁹⁴. A recent study in patients with alcoholic hepatitis portrayed a circulating microbiome signature, characterized by a decrease in Bacteroidetes and an enrichment of *Fusobacteria*, which are mainly present in the oral cavity¹⁹⁵. This phenomenon was paralleled by exacerbated endotoxaemia and activation of the type III secretion system, which has been associated with Gram-negative bacterial virulence. The presence of bacteria in other extra-intestinal tissues in humans with metabolic diseases has been debated, as they could not be detected in subcutaneous or adipose tissues in 14 individuals with obesity¹⁹⁶.

Notably, the critical role of intestinal barrier breach and microbial translocation extends beyond metabolic diseases and is observed in other chronic disorders. For example, a recent report demonstrated that a specific pathobiont (*Enterococcus gallinarum*) translocates into liver tissue, which triggered autoimmunity similar to systemic lupus erythematosus (SLE)¹⁹⁷. Treatment of lupus mouse models with vancomycin extended their lifespan and decreased circulating SLE-related autoantibody concentrations. Importantly, *E. gallinarum* could be detected in livers of patients with SLE and autoimmune hepatitis¹⁹⁷. Similarly, *L. reuteri*, a commensal abundant in some patients with SLE, was found to increase intestinal leakiness, translocate systemically and exacerbate a lupus-like phenotype in TLR7-dependent mouse models of SLE¹⁹⁸. Furthermore, specific strains of *Klebsiella pneumonia* obtained from patients with the biliary disease primary sclerosing cholangitis and transplanted into mice disrupted their intestinal barrier integrity and led to bacterial translocation of other pathobionts into the mesenteric lymph nodes and to the priming of a T_H17 cell response in the liver¹⁹⁹.

Altogether, these studies shed light on extra-intestinal and systemic translocation of the microbiome and its products in metabolic inflammation and reveal exciting perspectives beyond metabolic diseases.




Fig. 2 | Multiple ‘gastrointestinal hits’ contribute to metabolic diseases. The intestinal microbiota is modulated by environmental factors (such as diet and drugs) and host factors (such as the intestinal immune system and pancreatic and biliary secretions). For example, a typical Western diet alters the intestinal microbiota composition and function. Dysbiosis may represent an early event in metabolic diseases (1). A dysbiotic microbiota and dietary factors may trigger intestinal barrier dysfunction (2), which represents a further gastrointestinal hit. These intestinal alterations lead to the translocation of bacterial metabolites, such as phenylacetate, trimethylamine (TMA), imidazole propionate or mediators of metabolic dysregulation, and pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide, which drive chronic low-grade inflammation via the induction of proinflammatory cytokines such as IL-1 β . Metabolic inflammation and dysregulation bring about metabolic disease and are tightly interrelated. For example, metabolic inflammation (including increased IL-6 and tumour necrosis factor (TNF)) promotes insulin resistance. Consequently, it may be speculated that a diseased liver has an impaired capacity to clear bacteria and bacterial metabolites from the portal vein (3). This is supported by the presence of bacterial genes and molecular patterns in the systemic circulation and extraintestinal tissues in metabolic diseases. Collectively, the intestine and its resident microbiota emerge as drivers of metabolic inflammation and dysregulation, which are critical hallmarks of metabolic diseases such as obesity, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and associated atherosclerosis. TMAO, trimethylamine *N*-oxide.

Chronic inflammation and metabolic disease

Chronic low-grade inflammation is a crucial component in metabolic disorders such as obesity, T2D, NAFLD and atherosclerosis and associates with disease complications and prognosis^{200–203}. The adipose tissue and

liver serve as important sources of inflammatory mediators contributing to chronic inflammation and driving metabolic dysregulation²⁰⁴, and a wide range of immune cell populations can be found in inflamed metabolic tissues²⁰⁵. Prospective studies and meta-analyses linked high-sensitivity CRP (hsCRP) levels with cardiovascular risk^{206,207}. Studies have demonstrated that statins induced their lipid-lowering effect in part through inhibition of inflammation and that hsCRP levels were as prognostic of coronary artery disease as low-density lipoprotein serum concentrations^{208–210}. Along the same lines, several studies have shown that elevated levels of hsCRP were a reliable prognostic marker of cardiovascular complications in metabolic diseases, including T2D²⁰⁷. For atherosclerosis, the detrimental impact of chronic inflammation was underlined in the landmark CANTOS trial, as blockade of IL-1 β by canakinumab significantly lowered the rates of recurrent myocardial infarction and cardiovascular mortality in statin-treated patients, proving a key role for this cytokine in the pathogenesis of atherosclerosis²¹¹. Importantly, the benefits of canakinumab were directly associated with lowering hsCRP and IL-6 serum levels^{212,213}. Notably, several preclinical studies demonstrated that ‘proinflammatory’ consortia of gut microbiota could be transferred to animals, eliciting systemic inflammation and aggravating atherosclerosis²¹⁴. In contrast, bacteria such as *B. vulgatus* or *Bacteroides dorei* ameliorated endotoxaemia and improved atherosclerosis in mice²¹⁵, which somewhat conflicts with the clinical observation that *B. vulgatus* was associated with insulin resistance in T2D^{59,216} and that the prebiotic inulin-type fructan reduced its abundance in obese women²¹⁷.

Chronic inflammation in obesity, T2D and NAFLD might not only contribute to atherosclerosis and cardiovascular complications but also impact the course of the disease, for example, by modulation of insulin resistance in various tissues such as adipose tissue, liver and muscle^{5,218–221}. Inflammatory cytokines and transcription factors involved in the regulation of insulin resistance are highly expressed in metabolic tissues^{222,223}. Administration of IL-1 receptor antagonist to T2D subjects was able to improve glycaemic control. The improvement in insulin secretion lasted 39 weeks following the withdrawal of this therapy^{224,225}. However, canakinumab treatment was not able to reduce the incidence of T2D over a median period of 3.7 years and was not associated with long-term benefits on glycated haemoglobin levels²²⁶. However, this result does not rule out an impact of low-grade inflammation on glucose control. Further clinical studies in atherosclerosis targeting other inflammatory cytokines, such as TNF, are warranted.

Conclusions and future prospects

Mechanisms of chronic inflammation in metabolic disorders are complex and of diverse aetiologies²²⁷. As outlined in this Review, the gastrointestinal tract and its bacterial inhabitants have emerged as key regulators of metabolic inflammation and dysfunction. Future studies will identify which and how bacterial metabolites regulate immunometabolism. We propose a paradigm by which various ‘gastrointestinal hits’ such as dysbiosis

and barrier dysfunction may account for the evolution of metabolic diseases (FIG. 2). These events may promote metabolic inflammation and fuel metabolic perturbations^{37,228}. Such a cascade of events might be particularly relevant in lean subjects with T2D and NAFLD, in whom classical 'sterile' triggers of lipotoxic inflammation are lacking²²⁹.

Regulatory factors that impact the intestinal microbiota (for example, glucose availability) may similarly affect epithelial integrity¹³¹. Drawing traditional associations between specific pathogens and diseases (as characterized by Koch's postulates) may require a revision in the context of metabolic disorders, as no single responsible pathogen could be identified or cultured²³⁰. Such postulates should be challenged, as some commensals could become detrimental to their host (for example, by penetrating the intestinal barrier) under certain circumstances. One might also ask why such 'pathobionts' are not targeted by the immune system, how they trigger a chronic inflammatory response (rather than a

self-limited immune response) and how LPS impacts low-grade inflammatory human diseases. In this regard, a strain-specific host immune response was suggested to stem from distinct LPS subtypes in the context of autoimmunity¹⁶⁸.

Studies from the past years have established that chronic inflammation contributes to cardiovascular disease and affects the outcome of metabolic diseases such as obesity, NAFLD and T2D. Targeting inflammatory pathways has become attractive in atherosclerosis and may become pivotal in the treatment of other metabolic diseases in the future²¹¹. However, it may be more plausible to interfere at the site of origin of inflammation such as the gastrointestinal tract. The gut microbiota-metabolism axis has gained momentum in preclinical settings and opens an exciting new avenue for clinicians, which may similarly become relevant in other (for example, neurological) diseases^{231,232}.

Published online: 06 August 2019

- Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N. Engl. J. Med.* **336**, 973–979 (1997).
- Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N. Engl. J. Med.* **342**, 836–843 (2000).
- In 28,263 healthy postmenopausal women, high-sensitivity C-reactive protein was the strongest predictor of the risk of cardiovascular events.** Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E. & Ridker, P. M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* **286**, 327–334 (2001).
- Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. *Nature* **542**, 177–185 (2017).
- Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. *Nat. Rev. Immunol.* **11**, 98–107 (2011).
- Tilg, H. & Moschen, A. R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends Endocrinol. Metab.* **19**, 371–379 (2008).
- NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. *Nature* **569**, 260–264 (2019).
- Pickup, J. C., Mattock, M. B., Chusney, G. D. & Burt, D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. *Diabetologia* **40**, 1286–1292 (1997).
- Festa, A., D'Agostino, Jr., R., Tracy, R. P. & Haffner, S. M. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes* **51**, 1131–1137 (2002).
- Freeman, D. J. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. *Diabetes* **51**, 1596–1600 (2002).
- Thorand, B. et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. *Arch. Intern. Med.* **163**, 93–99 (2003).
- Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. *Nat. Rev. Gastroenterol. Hepatol.* **14**, 32–42 (2017).
- Park, S. H. et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. *J. Gastroenterol. Hepatol.* **19**, 694–698 (2004).
- Haukeland, J. W. et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. *J. Hepatol.* **44**, 1167–1174 (2006).
- Yoneda, M. et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. *J. Gastroenterol.* **42**, 573–582 (2007).
- Chiang, C. H., Huang, C. C., Chan, W. L., Chen, J. W. & Leu, H. B. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. *Clin. Biochem.* **43**, 1399–1404 (2010).
- Zimmermann, E. et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. *J. Hepatol.* **55**, 660–665 (2011).
- Pihlajamäki, J. et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. *J. Hepatol.* **56**, 663–670 (2012).
- Liang, H. et al. A low dose lipid infusion is sufficient to induce insulin resistance and a pro-inflammatory response in human subjects. *PLOS ONE* **13**, e0195810 (2018).
- Kubes, P. & Mehal, W. Z. Sterile inflammation in the liver. *Gastroenterology* **143**, 1158–1172 (2012).
- Ertunc, M. E. & Hotamisligil, G. S. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. *J. Lipid Res.* **57**, 2099–2114 (2016).
- Fu, S., Watkins, S. M. & Hotamisligil, G. S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. *Cell Metab.* **15**, 623–634 (2012).
- Hosogai, N. et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. *Diabetes* **56**, 901–911 (2007).
- Pasirica, M. et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. *Diabetes* **58**, 718–725 (2009).
- Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. & Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J. Biol. Chem.* **270**, 26746–26749 (1995).
- The first description and characterization of adiponectin, a key adipokine in humans.** Tilg, H. & Moschen, A. R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat. Rev. Immunol.* **6**, 772–783 (2006).
- Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* **259**, 87–91 (1993).
- The first study to prove a key role for TNF in obesity and insulin resistance in rodent models.** Kern, P. A. et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. *J. Clin. Invest.* **95**, 2111–2119 (1995).
- Fried, S. K., Bunkin, D. A. & Greenberg, A. S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. *J. Clin. Endocrinol. Metab.* **83**, 847–850 (1998).
- Moschen, A. R. et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression. *Cut* **59**, 1259–1264 (2010).
- Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor- α , in vivo. *J. Clin. Endocrinol. Metab.* **82**, 4196–4200 (1997).
- du Plessis, J. et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. *Gastroenterology* **149**, 635–648 (2015).
- Akira, S. & Takeda, K. Toll-like receptor signalling. *Nat. Rev. Immunol.* **4**, 499–511 (2004).
- O'Neill, L. A., Golenbock, D. & Bowie, A. G. The history of Toll-like receptors — redefining innate immunity. *Nat. Rev. Immunol.* **13**, 453–460 (2013).
- Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. *Cell* **140**, 805–820 (2010).
- Can, P. D. Human gut microbiome: hopes, threats and promises. *Cut* **67**, 1716–1725 (2018).
- Schroeder, B. O. & Backhed, F. Signals from the gut microbiota to distant organs in physiology and disease. *Nat. Med.* **22**, 1079–1089 (2016).
- Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. *Nature* **486**, 222–227 (2012).
- Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune system. *Nat. Rev. Immunol.* **17**, 219–232 (2017).
- Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10^{-/-} mice. *Nature* **487**, 104–108 (2012).
- This paper provides a mechanistic basis for how a Western-type diet might affect the prevalence of immune-mediated disorders such as inflammatory bowel disease.**
- Bischoff, S. C. et al. Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterol.* **14**, 189 (2014).
- Volynets, V. et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). *Dig. Dis. Sci.* **57**, 1932–1941 (2012).
- Mooradian, A. D., Morley, J. E., Levine, A. S., Prigge, W. F. & Gebhard, R. L. Abnormal intestinal permeability to sugars in diabetes mellitus. *Diabetologia* **29**, 221–224 (1986).
- Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. *N. Engl. J. Med.* **375**, 2369–2379 (2016).
- Gilbert, J. A. et al. Current understanding of the human microbiome. *Nat. Med.* **24**, 392–400 (2018).
- Deschasaux, M. et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. *Nat. Med.* **24**, 1526–1531 (2018).

47. Backhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. *Proc. Natl Acad. Sci. USA* **101**, 15718–15723 (2004).
48. Hooper, L. V. et al. Molecular analysis of commensal host-microbial relationships in the intestine. *Science* **291**, 881–884 (2001).
49. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* **444**, 1027–1031 (2006).
This study provides evidence that the obese microbiome in rodents has an increased capacity to harvest energy from the diet and that this trait is transmissible.
50. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. *Nature* **500**, 541–546 (2013).
51. Aron-Wisniewsky, J. et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. *Gut* **68**, 70–82 (2019).
52. Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. *Nature* **500**, 585–588 (2013).
53. Thaiss, C. A. et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. *Nature* **540**, 544–551 (2016).
54. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **490**, 55–60 (2012).
The first large human study from China demonstrating a gut microbiome signature in T2D.
55. Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* **498**, 99–103 (2013).
The first European study presenting evidence for compositional and functional changes in the metagenomes of women with T2D.
56. Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. *Cell Metab.* **25**, 1054–1062 (2017).
The first large study in a NAFLD population demonstrating a gut microbiome signature, especially in cases associated with advanced fibrosis.
57. Vrieze, A. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* **143**, 913–916 (2012).
58. Allin, K. H. et al. Aberrant intestinal microbiota in individuals with prediabetes. *Diabetologia* **61**, 810–820 (2018).
59. Pedersen, H. K. et al. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature* **535**, 376–381 (2016).
60. Udayappan, S. D. et al. Intestinal *Ralstonia pickettii* augments glucose intolerance in obesity. *PLOS ONE* **12**, e0181693 (2017).
61. Natividad, J. M. et al. *Bilophila wadsworthia* aggravates high fat diet induced metabolic dysfunctions in mice. *Nat. Commun.* **9**, 2802 (2018).
62. Udayappan, S. et al. Oral treatment with *Eubacterium hallii* improves insulin sensitivity in *db/db* mice. *NPJ Biofilms Microbiomes* **2**, 16009 (2016).
63. Zhao, L. et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science* **359**, 1151–1156 (2018).
A randomized clinical study demonstrating a beneficial effect of dietary fibres in subjects with T2D by modulating the gut microbiota.
64. Houghton, D. et al. Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes. *Diabetologia* **61**, 1700–1711 (2018).
65. Gentile, C. L. & Weir, T. L. The gut microbiota at the intersection of diet and human health. *Science* **362**, 776–780 (2018).
66. Kolodziejczyk, A. A., Zheng, D., Shibolet, O. & Elinav, E. The role of the microbiome in NAFLD and NASH. *EMBO Mol. Med.* **11**, e9302 (2018).
67. Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology* **63**, 764–775 (2016).
68. Mouzaki, M. et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology* **58**, 120–127 (2013).
69. Del Chierico, F. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. *Hepatology* **65**, 451–464 (2017).
70. Tilg, H., Cani, P. D. & Mayer, E. A. Gut microbiome and liver diseases. *Gut* **65**, 2035–2044 (2016).
71. Soderborg, T. K. et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. *Nat. Commun.* **9**, 4462 (2018).
72. Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. *Nature* **513**, 59–64 (2014).
73. Atarashi, K. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. *Science* **358**, 359–365 (2017).
This study provides evidence on how oral bacteria might colonize the intestinal tract and drive immune-mediated inflammatory disorders.
74. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* **482**, 179–185 (2012).
75. Fiordaliso, M. et al. Dietary oligofructose lowers triglycerides, phospholipids and cholesterol in serum and very low density lipoproteins of rats. *Lipids* **30**, 163–167 (1995).
76. Li, Z. et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology* **37**, 343–350 (2003).
77. Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. *Nat. Rev. Gastroenterol. Hepatol.* **16**, 35–56 (2019).
78. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* **56**, 1761–1772 (2007).
Landmark study demonstrating how endotoxins might affect metabolic disorders and associated inflammation.
79. Stenman, L. K., Holma, R. & Korpela, R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. *World J. Gastroenterol.* **18**, 923–929 (2012).
80. Jin, X., Yu, C. H., Lv, G. C. & Li, Y. M. Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. *World J. Gastroenterol.* **13**, 1732–1736 (2007).
81. Pendyala, S., Walker, J. M. & Holt, P. R. A high-fat diet is associated with endotoxemia that originates from the gut. *Gastroenterology* **142**, 1100–1101 (2012).
This study shows that a high-fat diet or Western-style diet in healthy human subjects leads to endotoxaemia.
82. Teixeira, T. F. et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. *Clin. Nutr.* **31**, 735–740 (2012).
83. Brignardello, J. et al. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. *Aliment. Pharmacol. Ther.* **32**, 1307–1314 (2010).
84. Genser, L. et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. *J. Pathol.* **246**, 217–230 (2018).
85. Laurans, L. et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. *Nat. Med.* **24**, 1113–1120 (2018).
86. Luther, J. et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. *Cell Mol. Gastroenterol. Hepatol.* **1**, 222–232 (2015).
87. Yuan, J. et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. *J. Gastroenterol. Hepatol.* **29**, 1292–1298 (2014).
88. Miele, L. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology* **49**, 1877–1887 (2009).
89. Strowski, M. Z. & Wiedenmann, B. Probiotic carbohydrates reduce intestinal permeability and inflammation in metabolic diseases. *Gut* **58**, 1044–1045 (2009).
90. Giorgio, V. et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. *Dig. Liver Dis.* **46**, 556–560 (2014).
91. Damms-Machado, A. et al. Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction. *Am. J. Clin. Nutr.* **105**, 127–135 (2017).
92. Peterson, L. W. & Artis, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat. Rev. Immunol.* **14**, 141–153 (2014).
93. Brown, E. M., Sadarangani, M. & Finlay, B. B. The role of the immune system in governing host-microbe interactions in the intestine. *Nat. Immunol.* **14**, 660–667 (2013).
94. McDole, J. R. et al. Goblet cells deliver luminal antigen to CD103⁺ dendritic cells in the small intestine. *Nature* **483**, 345–349 (2012).
95. Luck, H. et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. *Cell Metab.* **21**, 527–542 (2015).
This study shows that a gut-specific anti-inflammatory agent (5-aminosalicylic acid) improves bowel inflammation and metabolic parameters by reducing intestinal permeability and endotoxaemia.
96. Garidou, L. et al. The gut microbiota regulates intestinal CD4⁺ T cells expressing ROR γ and controls metabolic disease. *Cell Metab.* **22**, 100–112 (2015).
97. Johnson, A. M. et al. High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability. *PLOS ONE* **10**, e0122195 (2015).
98. Monteiro-Sepulveda, M. et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. *Cell Metab.* **22**, 113–124 (2015).
99. Ma, T. Y. et al. TNF- α -induced increase in intestinal epithelial tight junction permeability requires NF- κ B activation. *Am. J. Physiol. Gastrointest. Liver Physiol.* **286**, G367–G376 (2004).
100. Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin resistance. *Cell Metab.* **23**, 413–426 (2016).
101. Martinez-Lopez, M. et al. Microbiota sensing by mNcle-syk axis in dendritic cells regulates interleukin-17 and -22 production and promotes intestinal barrier integrity. *Immunity* **50**, 446–461 (2019).
102. Sonnenberg, G. F. et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. *Science* **336**, 1321–1325 (2012).
103. Kruglov, A. A. et al. Nonredundant function of soluble LT α 3 produced by innate lymphoid cells in intestinal homeostasis. *Science* **342**, 1243–1246 (2013).
104. Stockinger, B. & Omenetti, S. The dichotomous nature of T helper 17 cells. *Nat. Rev. Immunol.* **17**, 535–544 (2017).
105. Upadhyay, V. et al. Lymphotoxin regulates commensal responses to enable diet-induced obesity. *Nat. Immunol.* **13**, 947–953 (2012).
106. Pamin, N., McMillen, T. S., Edgel, K. A., Kim, F. & LeBoeuf, R. C. Deficiency of lymphotoxin- α does not exacerbate high-fat diet-induced obesity but does enhance inflammation in mice. *Am. J. Physiol. Endocrinol. Metab.* **302**, E961–E971 (2012).
107. Darnaud, M. et al. Enteric delivery of regenerating family member 3 α alters the intestinal microbiota and controls inflammation in mice with colitis. *Gastroenterology* **154**, 1009–1023 (2018).
108. Fatkhullina, A. R. et al. An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. *Immunity* **49**, 943–957 (2018).
This paper shows that inactivation of the IL-23–IL-22 signalling pathway deteriorates atherosclerosis by affecting intestinal barrier function, dysbiosis and expansion of pathogenic bacteria.
109. Aden, K. et al. Epithelial IL-23R signaling licenses protective IL-22 responses in intestinal inflammation. *Cell Rep.* **16**, 2208–2218 (2016).
110. Ngo, V. L. et al. A cytokine network involving IL-36 γ , IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage. *Proc. Natl Acad. Sci. USA* **115**, E5076–E5085 (2018).
111. Lee, J. S. et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. *Immunity* **43**, 727–738 (2015).
112. Mohammed, N., Tang, L., Jahangiri, A., de Villiers, W. & Eckhardt, E. Elevated IgG levels against specific bacterial antigens in obese patients with diabetes and in mice with diet-induced obesity and glucose intolerance. *Metabolism* **61**, 1211–1214 (2012).
113. Wang, X. et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. *Nature* **514**, 237–241 (2014).
114. Dalmas, E. et al. T cell-derived IL-22 amplifies IL-1 β -driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. *Diabetes* **63**, 1966–1977 (2014).
115. Fabbri, E. et al. Association between specific adipose tissue CD4⁺ T-cell populations and insulin resistance in obese individuals. *Gastroenterology* **145**, 366–374 (2013).
116. Sumarac-Dumanovic, M. et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. *Int. J. Obes.* **33**, 151–156 (2009).
117. Harley, I. T. et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. *Hepatology* **59**, 1830–1839 (2014).
118. Zuniga, L. A. et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. *J. Immunol.* **185**, 6947–6959 (2010).

119. Amar, J. et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. *EMBO Mol. Med.* **3**, 559–572 (2011).
120. Everard, A. et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. *Nat. Commun.* **5**, 5648 (2014).
121. Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science* **328**, 228–231 (2010).
In this study, it is shown that mice deficient in TLR5 develop hyperphagia and several features of metabolic syndrome, including obesity, hypertension, dyslipidaemia and insulin resistance.
122. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. *Nat. Immunol.* **12**, 408–415 (2011).
123. Stienstra, R. et al. Inflammasome is a central player in the induction of obesity and insulin resistance. *Proc. Natl Acad. Sci. USA* **108**, 15324–15329 (2011).
124. Levy, M. et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. *Cell* **163**, 1428–1443 (2015).
125. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. *Nature* **482**, 179–185 (2012).
126. Denou, E. et al. Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. *EMBO Mol. Med.* **7**, 259–274 (2015).
127. Ahuja, M. et al. Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. *Cell Metab.* **25**, 635–646 (2017).
128. Ding, S. et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. *PLOS ONE* **5**, e12191 (2010).
129. Ghoshal, S., Witta, J., Zhong, J., de Villiers, W. & Eckhardt, E. Chylomicrons promote intestinal absorption of lipopolysaccharides. *J. Lipid Res.* **50**, 90–97 (2009).
130. Laugerette, F. et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. *J. Nutr. Biochem.* **22**, 53–59 (2011).
131. Thaiss, C. A. et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. *Science* **359**, 1376–1383 (2018).
This study demonstrates the relevance of hyperglycaemia in regulation of the intestinal barrier and associated systemic inflammation.
132. Sellmann, C. et al. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. *J. Nutr. Biochem.* **26**, 1183–1192 (2015).
133. Chassaing, B. et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature* **519**, 92–96 (2015).
134. Elia, M., Goren, A., Behrens, R., Barber, R. W. & Neale, G. Effect of total starvation and very low calorie diets on intestinal permeability in man. *Clin. Sci.* **73**, 205–210 (1987).
135. Suzuki, T. & Hara, H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. *Nutr. Metab.* **7**, 19 (2010).
136. Tropini, C. et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. *Cell* **173**, 1742–1754 (2018).
137. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* **57**, 1470–1481 (2008).
In this study, antibiotic therapy improved systemic metabolic dysfunction and deletion of Cd14 in ob/ob mice mimicked the effects achieved by antibiotics.
138. Desai, M. S. et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. *Cell* **167**, 1339–1353 (2016).
139. Schroeder, B. O. et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. *Cell Host Microbe* **23**, 27–40 (2018).
140. Li, D. et al. Amelioration of intestinal barrier dysfunction by berberine in the treatment of nonalcoholic fatty liver disease in rats. *Pharmacogn. Mag.* **13**, 677–682 (2017).
141. Cani, P. D. et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. *Gut* **58**, 1091–1103 (2009).
142. Ghosh, S. S., Bie, J., Wang, J. & Ghosh, S. Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR^{-/-} mice-role of intestinal permeability and macrophage activation. *PLOS ONE* **9**, e108577 (2014).
143. Grandjean, C. et al. Recovery of ethanol-induced *Akkermansia muciniphila* depletion ameliorates alcoholic liver disease. *Gut* **67**, 891–901 (2017).
144. Plovier, H. et al. A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat. Med.* **23**, 107–113 (2017).
145. Wang, Y. et al. *Lactobacillus rhamnosus* GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. *Am. J. Physiol. Gastrointest. Liver Physiol.* **303**, G32–G41 (2012).
146. Natividad, J. M. et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. *Cell Metab.* **28**, 737–749 (2018).
147. Wang, K. et al. *Parabacteroides distans* alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. *Cell Rep.* **26**, 222–235 (2019).
148. Krumbäck, J. A. et al. Probiotic bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. *Microbiome* **6**, 121 (2018).
149. Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. *Immunity* **45**, 802–816 (2016).
150. Golden, J. M. et al. Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms. *Am. J. Physiol. Gastrointest. Liver Physiol.* **315**, G259–G271 (2018).
151. Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* **60**, 463–472 (2011).
152. Wahlstrom, A., Sayin, S. I., Marschall, H. U. & Backhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. *Cell Metab.* **24**, 41–50 (2016).
153. Suez, J., Zmora, N., Segal, E. & Elinav, E. The pros, cons, and many unknowns of probiotics. *Nat. Med.* **25**, 716–729 (2019).
154. Wei, X. et al. Fatty acid synthase modulates intestinal barrier function through palmitoylation of mucin 2. *Cell Host Microbe* **11**, 140–152 (2012).
155. Muccioli, G. G. et al. The endocannabinoid system links gut microbiota to adipogenesis. *Mol. Syst. Biol.* **6**, 392 (2010).
156. Jenne, C. N. & Kubes, P. Immune surveillance by the liver. *Nat. Immunol.* **14**, 996–1006 (2013).
157. Sun, L. et al. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. *Diabetes Care* **33**, 1925–1932 (2010).
158. Pussinen, P. J., Havulinna, A. S., Lehto, M., Sundvall, J. & Salomaa, V. Endotoxemia is associated with an increased risk of incident diabetes. *Diabetes Care* **34**, 392–397 (2011).
This paper shows that patients with diabetes have higher systemic endotoxin activity compared with non-diabetic individuals.
159. Camargo, A. et al. Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: from the CORDIOPREV study. *Clin. Nutr.* **38**, 529–538 (2018).
160. Mehta, N. N. et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. *Diabetes* **59**, 172–181 (2010).
161. Membrez, M. et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. *FASEB J* **22**, 2416–2426 (2008).
162. Pang, J. et al. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. *Aliment. Pharmacol. Ther.* **46**, 175–182 (2017).
163. Luche, E. et al. Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. *Mol. Metab.* **2**, 281–291 (2013).
164. Ye, D. et al. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. *Gut* **61**, 1058–1067 (2012).
165. Amar, J. et al. Energy intake is associated with endotoxemia in apparently healthy men. *Am. J. Clin. Nutr.* **87**, 1219–1223 (2008).
166. Cani, P. D. et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. *Diabetologia* **50**, 2374–2383 (2007).
167. Fabbiano, S. et al. Functional gut microbiota remodeling contributes to the caloric restriction-induced metabolic improvements. *Cell Metab.* **28**, 907–921 (2018).
168. Vatanen, T. et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. *Cell* **165**, 842–853 (2016).
169. Fei, N. & Zhao, L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. *ISME J.* **7**, 880–884 (2013).
170. Yang, Q., Vijayakumar, A. & Kahn, B. B. Metabolites as regulators of insulin sensitivity and metabolism. *Nat. Rev. Mol. Cell Biol.* **19**, 654–672 (2018).
171. Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. *Nat. Med.* **16**, 228–231 (2010).
172. Hergott, C. B. et al. Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis. *Blood* **127**, 2460–2471 (2016).
173. Chan, K. L. et al. Circulating NOD1 activators and hematopoietic NOD1 contribute to metabolic inflammation and insulin resistance. *Cell Rep.* **18**, 2415–2426 (2017).
174. Schertzer, J. D. et al. NOD1 activators link innate immunity to insulin resistance. *Diabetes* **60**, 2206–2215 (2011).
175. Cavallari, J. F. et al. Muramyl dipeptide-based postbiotics mitigate obesity-induced insulin resistance via IRF4. *Cell Metab.* **25**, 1063–1074 (2017).
176. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N. Engl. J. Med.* **368**, 1575–1584 (2013).
177. Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperactivity and thrombosis risk. *Cell* **165**, 111–124 (2016).
In this study, TMAO was characterized as a major gut-derived metabolite affecting platelet hyper-reactivity, suggesting a major role for the gastrointestinal tract in the pathogenesis of thrombosis.
178. Brown, J. M. & Hazen, S. L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. *Annu. Rev. Med.* **66**, 343–359 (2015).
179. Shan, Z. et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. *Am. J. Clin. Nutr.* **106**, 888–894 (2017).
180. Tang, W. H. et al. Increased trimethylamine-N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. *Clin. Chem.* **63**, 297–306 (2017).
181. Chen, Y. M. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. *Sci. Rep.* **6**, 19076 (2016).
182. Li, P. et al. Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus. *Am. J. Clin. Nutr.* **108**, 603–610 (2018).
183. Brown, J. M. & Hazen, S. L. Microbial modulation of cardiovascular disease. *Nat. Rev. Microbiol.* **16**, 171–181 (2018).
184. Tang, W. H. & Hazen, S. L. Microbiome, trimethylamine N-oxide, and cardiometabolic disease. *Transl. Res.* **179**, 108–115 (2017).
185. Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. *Nat. Rev. Immunol.* **16**, 341–352 (2016).
186. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Backhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell* **165**, 1332–1345 (2016).
187. Perry, R. J. et al. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. *Nature* **534**, 213–217 (2016).
188. Hoyle, L. et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. *Nat. Med.* **24**, 1070–1080 (2018).
In this study, the authors identify phenylacetic acid, a microbial product, as a trigger of hepatic steatosis, providing further evidence for a role of the gut microbiota in this process.

189. Koh, A. et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. *Cell* **175**, 947–961 (2018).
Here, imidazole propionate, a microbial metabolite derived from histidine, is shown to circulate at increased concentrations in patients with type 2 diabetes and contribute to insulin resistance.
190. Amar, J. et al. Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study. *PLOS ONE* **8**, e54461 (2013).
In this population-based study, the authors suggest a relationship between circulating blood microbiota, atherosclerosis and cardiovascular complications.
191. Potgieter, M., Bester, J., Kell, D. B. & Pretorius, E. The dormant blood microbiome in chronic, inflammatory diseases. *FEMS Microbiol. Rev.* **39**, 567–591 (2015).
192. Paise, S. et al. Comprehensive description of blood microbiome from healthy donors assessed by 16 S targeted metagenomic sequencing. *Transfusion* **56**, 1138–1147 (2016).
193. Schierwagen, R. et al. Circulating microbiome in blood of different circulatory compartments. *Gut* <https://doi.org/10.1136/gutjnl-2018-316227> (2018).
194. Lelouvier, B. et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. *Hepatology* **64**, 2015–2027 (2016).
195. Puri, P. et al. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. *Hepatology* **67**, 1284–1302 (2018).
This paper shows that heavy alcohol consumption affects intestinal barrier function and is associated with the appearance of a circulating microbiome.
196. Zulian, A. et al. Adipose tissue microbiota in humans: an open issue. *Int. J. Obes.* **40**, 1643–1648 (2016).
197. Manfredo Vieira, S. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. *Science* **359**, 1156–1161 (2018).
198. Zegarra-Ruiz, D. F. et al. A diet-sensitive commensal *Lactobacillus* strain mediates TLR7-dependent systemic autoimmunity. *Cell Host Microbe* **25**, 113–127 (2019).
199. Nakamoto, N. et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. *Nat. Microbiol.* **4**, 492–503 (2019).
200. Nathan, D. M. Long-term complications of diabetes mellitus. *N. Engl. J. Med.* **328**, 1676–1685 (1993).
201. Diehl, A. M. & Day, C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. *N. Engl. J. Med.* **377**, 2063–2072 (2017).
202. Chambers, J. C. et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. *Circulation* **104**, 145–150 (2001).
203. Visser, M., Bouter, L. M., McQuillan, G. M., Wener, M. H. & Harris, T. B. Low-grade systemic inflammation in overweight children. *Pediatrics* **107**, E13 (2001).
204. Lee, Y. S., Wollam, J. & Olefsky, J. M. An integrated view of immunometabolism. *Cell* **172**, 22–40 (2018).
205. Johnson, A. R., Milner, J. J. & Makowski, L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. *Immunol. Rev.* **249**, 218–238 (2012).
206. Emerging Risk Factors Collaboration, Kaptoge, S. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* **375**, 132–140 (2010).
207. Emerging Risk Factors Collaboration, Kaptoge, S. et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N. Engl. J. Med.* **367**, 1310–1320 (2012).
208. Nissen, S. E. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N. Engl. J. Med.* **352**, 29–38 (2005).
209. Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. *N. Engl. J. Med.* **352**, 20–28 (2005).
210. Ridker, P. M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N. Engl. J. Med.* **344**, 1959–1965 (2001).
211. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N. Engl. J. Med.* **377**, 1119–1131 (2017).
A landmark clinical study demonstrating a key role for IL-1 β in metabolic inflammation and associated cardiovascular complications.
212. Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* **391**, 319–328 (2018).
213. Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). *Eur. Heart J.* **39**, 3499–3507 (2018).
214. Brandsma, E. et al. A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. *Circ. Res.* **124**, 94–100 (2019).
215. Yoshida, N. et al. *Bacteroides vulgatus* and *Bacteroides dorei* reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. *Circulation* **138**, 2486–2498 (2018).
216. Leite, A. Z. et al. Detection of increased plasma interleukin-6 levels and prevalence of *Prevotella copri* and *Bacteroides vulgatus* in the feces of type 2 diabetes patients. *Front. Immunol.* **8**, 1107 (2017).
217. Dewulf, E. M. et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. *Gut* **62**, 1112–1121 (2013).
218. Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet* **383**, 1068–1083 (2014).
219. Johnson, A. M. & Olefsky, J. M. The origins and drivers of insulin resistance. *Cell* **152**, 673–684 (2013).
220. Tilg, H. & Moschen, A. R. Inflammatory mechanisms in the regulation of insulin resistance. *Mol. Med.* **14**, 222–231 (2008).
221. Samuel, V. T. & Shulman, G. I. Mechanisms for insulin resistance: common threads and missing links. *Cell* **148**, 852–871 (2012).
222. Kiechl, S. et al. Blockade of receptor activator of nuclear factor- κ B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. *Nat. Med.* **19**, 358–363 (2013).
223. Hotamisligil, G. S. Inflammation and metabolic disorders. *Nature* **444**, 860–867 (2006).
224. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N. Engl. J. Med.* **356**, 1517–1526 (2007).
225. Larsen, C. M. et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. *Diabetes Care* **32**, 1663–1668 (2009).
226. Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. *J. Am. Coll. Cardiol.* **71**, 2392–2401 (2018).
227. Netea, M. G. et al. A guiding map for inflammation. *Nat. Immunol.* **18**, 826–831 (2017).
228. Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* **52**, 1836–1846 (2010).
229. Mehal, W. Z. The Gordian Knot of dysbiosis, obesity and NAFLD. *Nat. Rev. Gastroenterol. Hepatol.* **10**, 637–644 (2013).
230. Evans, A. S. Causation and disease: the Henle-Koch postulates revisited. *Yale J. Biol. Med.* **49**, 175–195 (1976).
231. Fung, T. C., Olson, C. A. & Hsiao, E. Y. Interactions between the microbiota, immune and nervous systems in health and disease. *Nat. Neurosci.* **20**, 145–155 (2017).
232. Blander, J. M., Longman, R. S., Iliev, I. D., Sonnenberg, G. F. & Artis, D. Regulation of inflammation by microbiota interactions with the host. *Nat. Immunol.* **18**, 851–860 (2017).
233. Duan, Y. et al. Inflammatory links between high fat diets and diseases. *Front. Immunol.* **9**, 2649 (2018).
234. Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, P. D. & Backhed, F. Crosstalk between gut microbiota and dietary lipids aggravates wat inflammation through tlr signaling. *Cell Metab.* **22**, 658–668 (2015).
235. Roager, H. M. et al. Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial. *Gut* **68**, 83–93 (2019).
236. Mardinoglu, A. et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. *Cell Metab.* **27**, 559–571 (2018).
237. Yan, Y. et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. *Immunity* **38**, 1154–1163 (2013).
238. Mitchell, S. J. et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. *Cell Metab.* **27**, 667–676 (2018).
239. Agudelo, L. Z. et al. Kynurenic acid and Gpr35 regulate adipose tissue energy homeostasis and inflammation. *Cell Metab.* **27**, 378–392 (2018).
240. Syed, I. et al. Palmitic acid hydroxystearic acids activate gpr40, which is involved in their beneficial effects on glucose homeostasis. *Cell Metab.* **27**, 419–427 (2018).
241. Hatori, M. et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. *Cell Metab.* **15**, 848–860 (2012).
242. Clarke, S. F. et al. Exercise and associated dietary extremes impact on gut microbial diversity. *Gut* **63**, 1913–1920 (2014).
243. Geng, L. et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing fgf21 sensitivity in adipose tissues. *Cell Rep.* **26**, 2738–2752 (2019).
244. Segnifredo, F. B. et al. Weight-loss interventions and gut microbiota changes in overweight and obese patients: a systematic review. *Obes. Rev.* **18**, 832–851 (2017).
245. Ryan, K. K. et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. *Nature* **509**, 183–188 (2014).
246. Labrecque, J., Laforest, S., Michaud, A., Biertho, L. & Tchernof, A. Impact of bariatric surgery on white adipose tissue inflammation. *Can. J. Diabetes* **41**, 407–417 (2017).
247. Verbeek, J. et al. Roux-en-Y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. *Gut* **64**, 673–683 (2015).
248. de Groot, P. et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. *Gut* <https://doi.org/10.1136/gutjnl-2019-318320> (2019).
249. Rathinam, V. A. K., Zhao, Y. & Shao, F. Innate immunity to intracellular LPS. *Nat. Immunol.* **20**, 527–535 (2019).
250. Vijayan, A., Rumbo, M., Carnoy, C. & Sirard, J. C. Compartmentalized antimicrobial defenses in response to flagellin. *Trends Microbiol.* **26**, 423–435 (2018).
251. Wolf, A. J. & Underhill, D. M. Peptidoglycan recognition by the innate immune system. *Nat. Rev. Immunol.* **18**, 243–254 (2018).
252. Kanneganti, T. D. The signposts and winding roads to immunity and inflammation. *Nat. Rev. Immunol.* **19**, 81–82 (2019).
253. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. *Cell* **157**, 121–141 (2014).
254. Winkler, P., Ghadimi, D., Schrezenmeier, J. & Kraehenbuhl, J. P. Molecular and cellular basis of microflora-host interactions. *J. Nutr.* **137**, 756S–772S (2007).
255. Kotas, M. E. & Locksley, R. M. Why innate lymphoid cells? *Immunity* **48**, 1081–1090 (2018).
256. Kumar, V. & Ahmad, A. Role of MAIT cells in the immunopathogenesis of inflammatory diseases: new players in old game. *Int. Rev. Immunol.* **37**, 90–110 (2018).
257. Satoh, M. & Iwabuchi, K. Role of natural killer T cells in the development of obesity and insulin resistance: insights from recent progress. *Front. Immunol.* **9**, 1314 (2018).
258. Newton, R., Priyadarshini, B. & Turka, L. A. Immunometabolism of regulatory T cells. *Nat. Immunol.* **17**, 618–625 (2016).
259. Reilly, S. M. & Saltiel, A. R. Adapting to obesity with adipose tissue inflammation. *Nat. Rev. Endocrinol.* **13**, 633–643 (2017).
260. Shimizu, I., Yoshida, Y., Suda, M. & Minamino, T. DNA damage response and metabolic disease. *Cell Metab.* **20**, 967–977 (2014).
261. Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* **140**, 900–917 (2010).
262. Grazioli, S. & Pugin, J. Mitochondrial damage-associated molecular patterns: from inflammatory signaling to human diseases. *Front. Immunol.* **9**, 832 (2018).
263. Breton, J. et al. Gut commensal *E. coli* proteins activate host satiety pathways following nutrient-induced bacterial growth. *Cell Metab.* **23**, 324–334 (2016).

264. Cani, P. D. & de Vos, W. M. Next-generation beneficial microbes: the case of *Akkermansia muciniphila*. *Front. Microbiol.* **8**, 1765 (2017).
265. Maruvada, P., Leone, V., Kaplan, L. M. & Chang, E. B. The human microbiome and obesity: moving beyond associations. *Cell Host Microbe* **22**, 589–599 (2017).
266. Marchesi, J. R. et al. The gut microbiota and host health: a new clinical frontier. *Gut* **65**, 330–339 (2016).

Acknowledgements

The authors thank members of the Tilg and Elinav laboratories for discussions and apologize to authors whose work was not included due to space constraints. H.T. is supported by the Excellence Initiative (Competence Centres for Excellent Technologies — COMET) of the Austrian Research Promotion Agency FFG: Research Centre of Excellence in Vascular Ageing Tyrol, VASCage (K-Project No. 843536) funded by BMVIT, BMWFW, Wirtschaftsagentur Wien and Standortagentur Tirol. N.Z. is supported by a Gilead Biosciences Fellowship. T.E.A. is

grateful for the support from the Austrian Science Fund (FWF, P 29379-B28), the Austrian Society of Gastroenterology and Hepatology (ÖGGH), and the European Crohn's and Colitis Organization (ECCO). E.E. is supported by Y. and R. Ungar, the Abisch Frenkel Foundation for the Promotion of Life Sciences, the Gurwin Family Fund for Scientific Research, the Leona M. and Harry B. Helmsley Charitable Trust, the Crown Endowment Fund for Immunological Research, the estate of J. Gitlitz, the estate of L. Hershkovich, the Benozio Endowment Fund for the Advancement of Science, the Adelis Foundation, J.L. and V. Schwartz, A. and G. Markovitz, A. and C. Adelson, the French National Centre for Scientific Research (CNRS), D. L. Schwarz, the V. R. Schwartz Research Fellow Chair, L. Steinberg, J. N. Halpern, A. Edelheit, grants funded by the European Research Council, a Marie Curie Integration grant, the German–Israeli Foundation for Scientific Research and Development, the Israel Science Foundation, the Minerva Foundation, the Rising Tide Foundation, the Helmholtz Foundation, and the European Foundation for the Study of Diabetes. E.E. is a senior fellow of the Canadian Institute of Advanced Research (CIFAR) and an

international scholar of the Bill and Melinda Gates Foundation and Howard Hughes Medical Institute (HHMI).

Author contributions

All authors researched data for the article, made substantial contribution to discussion of content, and wrote, reviewed and edited the manuscript.

Competing interests

E.E. is a paid consultant for DayTwo and BiomX. The other authors declare no competing interests.

Peer review information

Nature Reviews Immunology thanks K. Clément, B. Jabri and O. Pedersen for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.